Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MyMD Pharmaceuticals, Inc. - Common Stock (NQ:MYMD)

1.820 UNCHANGED
Last Price Updated: 3:38 PM EDT, Jul 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MyMD Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
From TNF Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
Via AB Newswire
MyMD Pharmaceuticals Secures Strategic Investments
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates ‘Buy’ for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
Via AB Newswire
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
From MyMD Pharmaceuticals, Inc.
Via Business Wire
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Announces $15 Million Offering with Existing Investors
From MyMD Pharmaceuticals, Inc.
Via Business Wire
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.